Long-term safety of interferon beta-1b (IFNB-1b) treatment in early multiple sclerosis ( MS): The 11-year follow-up of BENEFIT (BENEFIT-11)

Mark S. Freedman , Ludwig Kappos (1) , Gilles Edan (2, 3) , Xavier Montalban (4) , Hans-Peter Hartung (5) , Bernhard Hemmer (6) , Edward Fox (7) , Frederik Barkhof (8) , Sven Schippling (9) , Andrea Schulze (10) , Dirk Pleimes (11) , Christoph Pohl (12, 13) , Rupert Sandbrink (14, 12) , Gustavo A. Suarez , Eva-Maria Wicklein (12)

1 Department of Biomedicine [Basel]
2 CIC - Centre d'Investigation Clinique [Rennes]
3 Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou]
4 Vall d'Hebron University Hospital [Barcelona]
5 Department of Neurology
6 SyNergy - Munich Cluster for systems neurology [Munich]
7 Central Texas Neurology Consultants [Round Rock]
8 VU University Medical Center [Amsterdam]
9 University hospital of Zurich [Zurich]
10 PAREXEL International [Berlin]
11 Myelo Therapeutics [Berlin]
12 Bayer Pharma AG [Berlin]
13 Rheinische Friedrich-Wilhelms-Universität Bonn
14 Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf]

Meeting Abstract: P028 - ACTRIMS Forum, New Orleans, LA, feb 2016

Domaines: Sciences du Vivant [q-bio]

Mark S. Freedman, Ludwig Kappos, Gilles Edan, Xavier Montalban, Hans-Peter Hartung, et al.. Long-term safety of interferon beta-1b (IFNB-1b) treatment in early multiple sclerosis ( MS): The 11-year follow-up of BENEFIT (BENEFIT-11). Multiple Sclerosis Journal, 2016, 22, pp.19--20. ⟨hal-01300794⟩